Latest Administration News

Neuren Pharmaceuticals has received official FDA minutes confirming the primary endpoints for its pivotal Phase 3 trial of NNZ-2591 targeting Phelan-McDermid syndrome, reinforcing the positive signals from earlier studies.

Life360, Inc. reported a strong Q1 2025 with 32% revenue growth to $103.6 million, driven by a 33% increase in subscription revenue and a return to profitability with $4.4 million net income. The company also advanced its strategic positioning through a $4.5 million acquisition and a key partnership.

Charter Hall Long WALE REIT has announced a 6.25 cents per stapled security distribution for the quarter ended March 31, 2025, featuring a significant AMIT Fund Payment component. This distribution reflects the REIT’s ongoing commitment to delivering steady income to investors under the Attribution Managed Investment Trust framework.

Yowie Group intensifies efforts to reclaim a substantial loan from Keybridge Capital, issuing a statutory demand and launching a share placement to shore up finances amid tariff challenges.

PolyNovo has secured Therapeutic Goods Administration clearance for thicker versions of its NovoSorb MTX product, broadening treatment options for complex wounds in Australia.

Mayne Pharma Group has acknowledged a delayed filing of a director's interest notice due to administrative oversight and is taking steps to reinforce compliance with ASX disclosure rules.

Vection Technologies has secured a strategic partnership with Area 12 Consulting, guaranteeing $0.5 million in annual recurring revenue for its Algho AI platform. This deal marks a significant step in expanding Vection's footprint in the generative AI and digital transformation space.

Alcoa Corporation has announced a quarterly dividend of USD 0.10 per security, payable on June 6, 2025, with a 30% default U.S. withholding tax applying to non-resident holders unless tax treaty benefits are claimed.

News Corporation reported a 3% revenue increase to $2.009 billion for Q3 2025, with net income attributable to stockholders tripling to $137 million. The company completed the strategic sale of Foxtel, marking a significant shift in its operations.

The NSW Court of Appeal has dismissed an appeal challenging the replacement of Keybridge Capital's directors and confirmed the end of its external administration, marking a pivotal governance shift for the investment group.

AVITA Medical reported a strong first quarter with revenues up 67% to $18.5 million, driven by expanded commercial sales and new product introductions. Despite a narrower net loss, the company faces ongoing challenges from revenue covenants and macroeconomic pressures.

Australian Bond Exchange Holdings (ASX: ABE) announces the resignation of director Anthony Hartman and the appointment of Robert Shaw and Mark O’Leary to its board, signaling a strategic boost in expertise.